CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity
OTTAWA, Jan. 11, 2018 /CNW/ – CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty”) and Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus”) (together the “Partners”), today announced a collaboration (the “JV”) to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders.
CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by clinical data focused on the medical community. The collaboration will leverage CannaRoyalty’s deep expertise in identifying, funding and commercializing cannabis related products in California and Aequus’ expertise in clinical development and drug delivery, and commercializing differentiated therapeutics in Canada.
CannaRoyalty intends to contribute its 10% equity stake in Bodhi Research Development
... read more at: http://markets.businessinsider.com/news/stocks/CannaRoyalty-and-Aequus-Pharmaceuticals-Announce-Joint-Venture-to-Develop-and-Commercialize-Cannabis-Based-Therapies-Targeting-Neurological-Disorders-477649